FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095894081> ?p ?o ?g. }

• W2095894081 endingPage "71" @default.
• W2095894081 startingPage "63" @default.
• W2095894081 abstract "The global control and management of tuberculosis (TB) is faced with the formidable challenge of worsening scenarios of drug-resistant disease. Pyrazinamide (PZA) is an indispensable first-line drug used for the treatment of TB. It plays a key role in reducing TB relapse rates, shortening the course of the disease treatment from 9-12 months to 6 months, and the treatment of patients infected with bacillary strains that are resistant to at least isoniazid and rifampicin. Additionally, it is the only first-line anti-TB drug most likely to be maintained in all new regimens, which are aimed at reducing the treatment period of susceptible, multi-drug resistant and extensively drug-resistant TB. It has a preferential sterilizing activity against non-replicating persister bacilli with low metabolism at acid pH in vitro or in vivo during active inflammation where other drugs may not act so well. PZA seem to have a non-specific cellular target and instead, exerts its anti-mycobacterial effect by disrupting the membrane energetics, the trans-translation process, acidification of the cytoplasm and perhaps coenzyme A synthesis, which is required for survival of Mycobacterium tuberculosis (MTB) persisters. Indeed, the emergence of MTB strains resistant to PZA represents an important clinical and public health problem. The essential role of PZA in TB treatment underlines the need for accurate and rapid detection of its resistance. This article presents an updated review of the molecular mechanisms of drug action and resistance in MTB against PZA, commenting on the several research gaps and proposed drug targets for PZA." @default.
• W2095894081 created "2016-06-24" @default.
• W2095894081 creator A5001981110 @default.
• W2095894081 creator A5002439541 @default.
• W2095894081 creator A5020628396 @default.
• W2095894081 creator A5022407487 @default.
• W2095894081 creator A5029255904 @default.
• W2095894081 creator A5033938302 @default.
• W2095894081 creator A5050213145 @default.
• W2095894081 creator A5066738831 @default.
• W2095894081 date "2016-03-01" @default.
• W2095894081 modified "2023-10-17" @default.
• W2095894081 title "Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update" @default.
• W2095894081 cites W1921865751 @default.
• W2095894081 cites W1923394711 @default.
• W2095894081 cites W1965013971 @default.
• W2095894081 cites W1966448483 @default.
• W2095894081 cites W1975610050 @default.
• W2095894081 cites W1980086670 @default.
• W2095894081 cites W1985658574 @default.
• W2095894081 cites W1986538901 @default.
• W2095894081 cites W1988971060 @default.
• W2095894081 cites W1991051142 @default.
• W2095894081 cites W1991957921 @default.
• W2095894081 cites W1995309322 @default.
• W2095894081 cites W1998828531 @default.
• W2095894081 cites W2000705873 @default.
• W2095894081 cites W2001414564 @default.
• W2095894081 cites W2001878369 @default.
• W2095894081 cites W2004494514 @default.
• W2095894081 cites W2004753123 @default.
• W2095894081 cites W2006545725 @default.
• W2095894081 cites W2014347011 @default.
• W2095894081 cites W2014425370 @default.
• W2095894081 cites W2018570582 @default.
• W2095894081 cites W2025275625 @default.
• W2095894081 cites W2025813566 @default.
• W2095894081 cites W2027132676 @default.
• W2095894081 cites W2034229074 @default.
• W2095894081 cites W2039394359 @default.
• W2095894081 cites W2044575327 @default.
• W2095894081 cites W2049273999 @default.
• W2095894081 cites W2050026866 @default.
• W2095894081 cites W2057369230 @default.
• W2095894081 cites W2061417565 @default.
• W2095894081 cites W2065130119 @default.
• W2095894081 cites W2066204878 @default.
• W2095894081 cites W2068927532 @default.
• W2095894081 cites W2071192895 @default.
• W2095894081 cites W2075505441 @default.
• W2095894081 cites W2077433872 @default.
• W2095894081 cites W2078221690 @default.
• W2095894081 cites W2082445705 @default.
• W2095894081 cites W2083155903 @default.
• W2095894081 cites W2091372367 @default.
• W2095894081 cites W2093036185 @default.
• W2095894081 cites W2096742175 @default.
• W2095894081 cites W2098335911 @default.
• W2095894081 cites W2099109129 @default.
• W2095894081 cites W2102321517 @default.
• W2095894081 cites W2103728832 @default.
• W2095894081 cites W2105977990 @default.
• W2095894081 cites W2108059857 @default.
• W2095894081 cites W2109719233 @default.
• W2095894081 cites W2115822252 @default.
• W2095894081 cites W2116120730 @default.
• W2095894081 cites W2121886790 @default.
• W2095894081 cites W2123158511 @default.
• W2095894081 cites W2128020518 @default.
• W2095894081 cites W2135378152 @default.
• W2095894081 cites W2138751689 @default.
• W2095894081 cites W2140437950 @default.
• W2095894081 cites W2140803600 @default.
• W2095894081 cites W2140934532 @default.
• W2095894081 cites W2141443223 @default.
• W2095894081 cites W2142086874 @default.
• W2095894081 cites W2146817473 @default.
• W2095894081 cites W2147251439 @default.
• W2095894081 cites W2148919591 @default.
• W2095894081 cites W2149808870 @default.
• W2095894081 cites W2156272262 @default.
• W2095894081 cites W2161340676 @default.
• W2095894081 cites W2164007000 @default.
• W2095894081 cites W2165048471 @default.
• W2095894081 cites W2320476413 @default.
• W2095894081 cites W4213353716 @default.
• W2095894081 cites W4229917921 @default.
• W2095894081 cites W4246274378 @default.
• W2095894081 doi "https://doi.org/10.1016/j.advms.2015.09.007" @default.
• W2095894081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26521205" @default.
• W2095894081 hasPublicationYear "2016" @default.
• W2095894081 type Work @default.
• W2095894081 sameAs 2095894081 @default.
• W2095894081 citedByCount "74" @default.
• W2095894081 countsByYear W20958940812016 @default.
• W2095894081 countsByYear W20958940812017 @default.
• W2095894081 countsByYear W20958940812018 @default.
• W2095894081 countsByYear W20958940812019 @default.

• next